{"protocolSection":{"identificationModule":{"nctId":"NCT03329911","orgStudyIdInfo":{"id":"BAT1706-003-CR"},"organization":{"fullName":"Bio-Thera Solutions","class":"INDUSTRY"},"briefTitle":"A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer","officialTitle":"A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin® Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2021-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-10-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-05","type":"ACTUAL"},"completionDateStruct":{"date":"2021-05-27","type":"ACTUAL"},"studyFirstSubmitDate":"2017-10-20","studyFirstSubmitQcDate":"2017-10-31","studyFirstPostDateStruct":{"date":"2017-11-06","type":"ACTUAL"},"resultsFirstSubmitDate":"2020-11-05","resultsFirstSubmitQcDate":"2021-08-17","resultsFirstPostDateStruct":{"date":"2021-09-13","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-09-13","lastUpdatePostDateStruct":{"date":"2021-09-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bio-Thera Solutions","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®."},"conditionsModule":{"conditions":["Non-squamous Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":651,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"EU Avastin®","type":"ACTIVE_COMPARATOR","description":"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles","interventionNames":["Drug: EU Avastin®","Drug: Paclitaxel","Drug: carboplatin"]},{"label":"BAT1706","type":"EXPERIMENTAL","description":"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles","interventionNames":["Drug: BAT1706","Drug: Paclitaxel","Drug: carboplatin"]}],"interventions":[{"type":"DRUG","name":"EU Avastin®","description":"100 mg/4 mL","armGroupLabels":["EU Avastin®"]},{"type":"DRUG","name":"BAT1706","description":"100 mg/4 mL","armGroupLabels":["BAT1706"]},{"type":"DRUG","name":"Paclitaxel","description":"200 mg/m²","armGroupLabels":["BAT1706","EU Avastin®"]},{"type":"DRUG","name":"carboplatin","description":"target area under the curve \\[AUC\\] 6 mg/mL•minute","armGroupLabels":["BAT1706","EU Avastin®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate","description":"The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data:\n\nCR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)","timeFrame":"Week 18"}],"secondaryOutcomes":[{"measure":"Progression Free Survival Rate","description":"Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.","timeFrame":"8 months,1 year and 2 years"},{"measure":"Progression Free Survival Time","description":"Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.","timeFrame":"8 months,1 year and 2 years"},{"measure":"Overall Survival Rate","description":"Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.","timeFrame":"8 months,1 year and 2 years"},{"measure":"Overall Survival Time","description":"Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.","timeFrame":"8 months,1 year and 2 years"},{"measure":"Overall Response Rate","description":"ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.","timeFrame":"Week 6 and Week 12"},{"measure":"Duration of Response","description":"Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.","timeFrame":"8 months"}],"otherOutcomes":[{"measure":"Plasma Level of Anti Drug Antibodies (ADA) and Neutralizing Anti-drug Antibodies (NADA) Correlated With Bevacizumab Plasma Level","description":"Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level","timeFrame":"12 months"},{"measure":"Bevacizumab Plasma Exposure Following Treatments of BAT1706 or EU Avastin®","description":"Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®","timeFrame":"12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Stage IV nsNSCLC or recurrent disease (any Stage at initial diagnosis) no longer amenable to curative surgery or local therapy (histologically or cytologically confirmed).\n2. No prior systemic therapy for metastatic disease. Prior systemic therapy and/or radiotherapy for locally advanced disease is permitted if completed ≥ 6 months prior to randomization.\n3. Tumors without activating EGFR or ALK mutation. Patients with unknown mutation status or known activating EGFR or ALK mutation may be included provided the corresponding targeted agent is not available and chemotherapy is the standard of care of the study center.\n4. At least one measurable target lesion according to RECIST 1.1 (Appendix 13.4) as confirmed by CIR; bone only and brain-only metastases are not allowed. Lesions previously treated with radiotherapy are non-target lesion.\n5. Eastern Cooperative Oncology Group performance status of 0 or 1 and life expectancy \\> 3 months based on Investigator's judgment.\n\nExclusion Criteria:\n\n1. Diagnosis of small cell carcinoma of the lung, mixed predominant squamous cell carcinoma of the lung, NSCLC not otherwise specified.\n2. Tumor cavitation, tumor invading into large blood vessels or close to large vessels with an increased risk of bleeding, according to Investigator's judgment.\n3. Prior therapy with monoclonal antibodies or small molecule inhibitors against VEGF or VEGFR, including Avastin®.\n4. Prior systemic therapy for metastatic disease.\n5. Prior systemic anticancer therapy, or radiotherapy for locally advanced nsNSCLC if completed \\< 6 months prior to screening.\n6. Previous malignancy other than NSCLC in the last 5 years except for basal cell cancer of the skin or pre invasive cancer of the cervix.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Shengfeng Li","affiliation":"Sponsor GmbH","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"The First Affiliated Hospital of Xiamen University","city":"Xiamen","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Clinical Medical Research S.C.","city":"Orizaba","zip":"94300","country":"Mexico","geoPoint":{"lat":18.85195,"lon":-97.09957}},{"facility":"National Hospital Oncology","city":"Bloemfontein","zip":"9301","country":"South Africa","geoPoint":{"lat":-29.12107,"lon":26.214}},{"facility":"Baskent University Ankara Hospital","city":"Ankara","zip":"6000","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"CI Kryvyi Rih Oncological Dispensary of DRC","city":"Kryvyi Rih","zip":"53213","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"EU Avastin®","description":"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nEU Avastin®: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"},{"id":"FG001","title":"BAT1706","description":"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nBAT1706: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"326"},{"groupId":"FG001","numSubjects":"325"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"209"},{"groupId":"FG001","numSubjects":"222"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"117"},{"groupId":"FG001","numSubjects":"103"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"EU Avastin®","description":"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nEU Avastin®: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"},{"id":"BG001","title":"BAT1706","description":"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nBAT1706: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"326"},{"groupId":"BG001","value":"325"},{"groupId":"BG002","value":"651"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"208"},{"groupId":"BG001","value":"233"},{"groupId":"BG002","value":"441"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"118"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"210"}]}]}]},{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60","lowerLimit":"26","upperLimit":"88"},{"groupId":"BG001","value":"61","lowerLimit":"27","upperLimit":"84"},{"groupId":"BG002","value":"61","lowerLimit":"26","upperLimit":"88"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"194"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"229"},{"groupId":"BG001","value":"228"},{"groupId":"BG002","value":"457"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"24"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"140"},{"groupId":"BG001","value":"141"},{"groupId":"BG002","value":"281"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"171"},{"groupId":"BG001","value":"172"},{"groupId":"BG002","value":"343"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Turkey","categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"131"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"140"},{"groupId":"BG002","value":"279"}]}]},{"title":"Ukraine","categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"102"},{"groupId":"BG002","value":"200"}]}]},{"title":"South Africa","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"8"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"33"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Response Rate","description":"The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data:\n\nCR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Week 18","groups":[{"id":"OG000","title":"EU Avastin®","description":"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nEU Avastin®: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"},{"id":"OG001","title":"BAT1706","description":"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nBAT1706: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"326"},{"groupId":"OG001","value":"325"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156"},{"groupId":"OG001","value":"145"}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival Rate","description":"Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"8 months,1 year and 2 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Progression Free Survival Time","description":"Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"8 months,1 year and 2 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival Rate","description":"Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"8 months,1 year and 2 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Survival Time","description":"Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.","reportingStatus":"NOT_POSTED","timeFrame":"8 months,1 year and 2 years","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Overall Response Rate","description":"ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.","reportingStatus":"NOT_POSTED","timeFrame":"Week 6 and Week 12","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.","reportingStatus":"NOT_POSTED","timeFrame":"8 months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Plasma Level of Anti Drug Antibodies (ADA) and Neutralizing Anti-drug Antibodies (NADA) Correlated With Bevacizumab Plasma Level","description":"Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level","reportingStatus":"NOT_POSTED","timeFrame":"12 months","denomUnitsSelected":"Participants"},{"type":"OTHER_PRE_SPECIFIED","title":"Bevacizumab Plasma Exposure Following Treatments of BAT1706 or EU Avastin®","description":"Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®","reportingStatus":"NOT_POSTED","timeFrame":"12 months","denomUnitsSelected":"Participants"}]},"adverseEventsModule":{"frequencyThreshold":"0.3","timeFrame":"From the start of the first study medication administration until 28 days after discontinuation/completion of the study medication or up to Week 53 after randomization- All AEs, regardless of relationship to the study medication/study procedures. During the LTE study, only adverse events of special interest (AESIs) and SAEs until 28 days after the subject's last dose will be collected.","eventGroups":[{"id":"EG000","title":"EU Avastin®","description":"Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nEU Avastin®: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute","deathsNumAffected":4,"deathsNumAtRisk":324,"seriousNumAffected":119,"seriousNumAtRisk":324,"otherNumAffected":8,"otherNumAtRisk":324},{"id":"EG001","title":"BAT1706","description":"BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months.\n\nDrug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles\n\nDrug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles\n\nBAT1706: 100 mg/4 mL\n\nPaclitaxel: 200 mg/m²\n\ncarboplatin: target area under the curve \\[AUC\\] 6 mg/mL•minute","deathsNumAffected":7,"deathsNumAtRisk":325,"seriousNumAffected":119,"seriousNumAtRisk":325,"otherNumAffected":9,"otherNumAtRisk":325}],"seriousEvents":[{"term":"Blood and lymphatic system disorders","organSystem":"Blood and lymphatic system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":324},{"groupId":"EG001","numAffected":31,"numAtRisk":325}]},{"term":"Infections and infestations","organSystem":"Infections and infestations","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":324},{"groupId":"EG001","numAffected":27,"numAtRisk":325}]},{"term":"Respiratory, thoracic and mediastinal disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":324},{"groupId":"EG001","numAffected":21,"numAtRisk":325}]},{"term":"Gastrointestinal disorders","organSystem":"General disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":324},{"groupId":"EG001","numAffected":12,"numAtRisk":325}]},{"term":"Cardiac disorders","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":324},{"groupId":"EG001","numAffected":11,"numAtRisk":325}]},{"term":"Vascular disorders","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":324},{"groupId":"EG001","numAffected":5,"numAtRisk":325}]},{"term":"General disorders and administration site conditions","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":324},{"groupId":"EG001","numAffected":8,"numAtRisk":325}]},{"term":"Nervous system disorders","organSystem":"Nervous system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":324},{"groupId":"EG001","numAffected":4,"numAtRisk":325}]}],"otherEvents":[{"term":"Neoplasms benign, malignant and unspecified (inclcysts and polyps)","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":0,"numAtRisk":325}]},{"term":"Hepatobiliarydisorders","organSystem":"Hepatobiliary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":324},{"groupId":"EG001","numAffected":1,"numAtRisk":325}]},{"term":"Renal and urinary disorders","organSystem":"Renal and urinary disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":324},{"groupId":"EG001","numAffected":3,"numAtRisk":325}]},{"term":"Musculoskeletal and connective tissue disorders","organSystem":"Musculoskeletal and connective tissue disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":324},{"groupId":"EG001","numAffected":5,"numAtRisk":325}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"Yufeng Zhang","organization":"Bio-Thera Solutions Ltd.","email":"yfzhang@bio-thera.com","phone":"+86 2038251386"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-06-20","uploadDate":"2021-08-17T22:03","filename":"Prot_002.pdf","size":1012925},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-11-28","uploadDate":"2021-08-15T23:05","filename":"SAP_003.pdf","size":1926524}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["United States"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2020-12-04","type":"ACTUAL"}}}},"interventionBrowseModule":{"meshes":[{"id":"D017239","term":"Paclitaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}